Log in to search using one of your social media accounts:

 

Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years

The treatments could help hundreds of thousands of men worldwide stave off pain and chemotherapy, but researchers don ’ t yet know if they will extend lives.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Prostate Cancer Source Type: news

Related Links:

AbstractPurposeTo gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC).MethodsPatients  ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of lif e, ECOG-performance status, and physicians’ and patients’ perception of health were documented. Reasons for and fact...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ch L Abstract PURPOSE: To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC). METHODS: Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians' and patients' perception of health were documented. Reasons f...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
Pain treatment in patients with bone metastasized advanced prostate cancer is often challenging. A range of treatment modalities are available to control prostate cancer-specific pain, such as androgen deprivation therapies, taxane-based chemotherapy, radionuclide therapy with radium-223 or palliative radiotherapy. In addition, analgesics are commonly used for direct symptom management.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Tags: Letter Source Type: research
ConclusionsRandomized trials testing new drugs as maintenance can be successfully conducted after chemotherapy in castrate-resistant prostate cancer. Maintenance tasquinimod therapy significantly reduced the risk of rPFS by 40%.ClinicalTrialsgov identifier NCT01732549.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Abstract Since November 2013, the alpha emitter radium-223 dichloride (Alpharadin/Xofigo®) has been approved for the treatment of men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. In the ASYMPCA clinical trial, radium-223 was shown to improve overall survival and to reduce the time to the first symptomatic skeletal event. The use of radium-223 was associated with a reduction of pain and an improvement of health-related quality of life compared to the placebo arm. The efficacy of radium-223 dichloride was not inhibited by the use...
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
Conclusions AAP significantly improved outcomes in mCRPC patients compared with prednisone alone regardless of baseline pain and PSA level, and GS at primary diagnosis with no significant differences between observed treatment effects in groups 1 and 2. Patient summary Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis. This post hoc analysis of the pivotal COU-A...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conclusions Enzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment. Patient summary Patients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment. In this prospective, single-arm study, enzalutamide showed antitumour activity in some patients with metastatic castration-resistant prostate ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
A standard approach for treating aggressive prostate cancer is to give therapies that block testosterone, a tumor-stimulating hormone. Should initial hormonal therapies fail, doctors can switch to other drugs that suppress testosterone in different ways. One of them, a drug called abiraterone, has been shown to significantly extend lifespans in men who have become resistant to other hormonal treatments. But in June, two major studies reported simultaneously that abiraterone also prolongs life in men with aggressive prostate cancer that’s been newly diagnosed. One of the studies, a phase 3 clinical trial called LATITU...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Health Men's Health Prostate Health Source Type: blogs
Abstract Prostate cancer is the first cancer in men and has a specific tropism to bones. This tropism provided the rationale to develop bone targeting radiopharmaceutical agents, such as strontium, samarium and more recently the Radium-223, an alpha-emitter. In a phase III trial, ALSYMPCA, Radium-223 not only improved pain relief, but also impacted on overall survival. Despite an approval by both FDA and EMA, prescription of this agent remains limited by the lack of refund, especially in France. Radium-223 is currently evaluated in several clinical trials (combination with chemotherapy, radiotherapy or h...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
Conclusion Hardware failure is a risk for all patients who undergo instrumentation following resection for metastatic spine tumors. This study identified that pre-operative radiation may increase the risk for hardware failure in this population.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Pain | Prostate Cancer